Status:
COMPLETED
Clinical Evaluation of Florbetapir in Primary Progressive Aphasia
Lead Sponsor:
University of Chicago
Conditions:
Primary Progressive Aphasia
Alzheimer Disease
Eligibility:
All Genders
18+ years
Brief Summary
The purpose of this research is to better understand how dementia affects activity in different parts of the brain.
Detailed Description
This study is being done to examine the usefulness of Positron Emission Tomography (PET) imaging with florbetapir F 18 as a biomarker in the identification of amyloid-ß peptide (Aß) in the brain. Amyl...
Eligibility Criteria
Inclusion
- Subjects who, in the opinion of the investigator, can tolerate the PET scan procedures
Exclusion
- Clinically significant cardiovascular disease
- clinically significant hepatic, renal, pulmonary, metabolic, or endocrine disturbances
- Pregnant
- Breastfeeding
- Women of childbearing potential who are not surgically sterile, not refraining from sexual activity or not using reliable methods of contraception.
- History of relevant severe drug allergy or hypersensitivity
- Patients who have received an investigational medication under an FDA Investigational New Drug (IND) protocol within the last 30 days.
Key Trial Info
Start Date :
March 15 2012
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
February 28 2017
Estimated Enrollment :
48 Patients enrolled
Trial Details
Trial ID
NCT04726527
Start Date
March 15 2012
End Date
February 28 2017
Last Update
October 16 2024
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
The Healthy Aging & Alzheimer's Research Care Center - University of Chicago
Chicago, Illinois, United States, 60637